Medyczne Laboratorium Diagnostyka
- Address
- Mickiewicza 2, 60-834 Poznan, Poland
Medyczne Laboratorium Diagnostyka - Advanced Lung Cancer Research
Medyczne Laboratorium Diagnostyka is a clinical research facility specializing in oncology trials, with a particular focus on advanced thoracic malignancies. The center conducts sophisticated comparative effectiveness studies evaluating novel therapeutic agents against standard-of-care treatments in previously treated cancer patients.
- Advanced and metastatic non-small cell lung cancer (NSCLC) treatment optimization
- Targeted antibody-drug conjugate therapies and molecular innovations
- Comparative efficacy trials in patients with actionable genomic alterations
The facility demonstrates expertise in managing complex oncology protocols that assess both progression-free survival and overall survival outcomes. Their research portfolio includes investigations of cutting-edge treatments for patients who have exhausted first-line therapy options, with particular attention to tumors both with and without specific actionable genomic alterations, representing a comprehensive approach to personalized cancer medicine.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medyczne Laboratorium Diagnostyka
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 3 Randomized Trial of Datopotamab Deruxtecan Versus Docetaxel in Advanced or Metastatic Non-Small Cell Lung Cancer with or without Genomic Alterations | Daiichi Sankyo Inc. | Phase III | Not Recruiting | Apr 2021 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Datopotamab Deruxtecan | 1 | Unknown | 2021-04-30 | 2021-04-30 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.